Full Press Release Details
NeuroSense Reports First Quarter 2023 Financial Results & Provides Business Update: Phase 2b
ALS Trial Completes Enrollment, Topline
Data Expected Q4 2023
CAMBRIDGE, Mass., June 1, 2023 /PRNewswire/ -- NeuroSense
Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today
announced financial results for the quarter ended March 31, 2023 and provided a business update.
"Having completed patient enrollment in our Phase 2b amyotrophic
lateral sclerosis (ALS) trial, we are optimistic that topline results may offer new hope for people living with ALS and may generate a
major inflection point for NeuroSense as we advance our combination therapy, PrimeC, toward market," stated NeuroSense's CEO, Alon
Ben-Noon. "As we witness the trend of successful combination therapy strategies for neurodegenerative diseases, PrimeC has the added
advantage of offering both a synergistic mechanism of action and an improved pharmacokinetic profile to enhance efficacy. We see the fact
that nearly all PARADIGM participants who have completed the 6-month trial to date have chosen to continue receiving PrimeC for 12 more
months as a positive signal."
In May 2023, NeuroSense announced the completion of enrollment in
PARADIGM, (NCT05357950), a multinational, randomized, double-blind, placebo-controlled Phase 2b clinical trial of PrimeC in people
living with ALS. The clinical trial is evaluating PrimeC's efficacy, as well as safety and tolerability. Study participants are dosed
for six months after being randomized 2:1 to receive PrimeC or placebo, respectively. Participants who complete the 6-month study have
the option to be treated with PrimeC during a 12-month open label extension
(OLE) phase. 96% of participants who completed the 6-month portion of the trial have opted to continue with the OLE. Topline results
for the six month study are expected in Q4 2023.
an AD biomarker study completed in Q1 2023 demonstrated the therapeutic potential of NeuroSense's combination drug platform for AD. The
study revealed elevated levels of the novel biomarker TDP-43 in AD as compared to the healthy control group. NeruoSense's platform has
already shown a statistically significant reduction of TDP-43 in a prior Phase 2a clinical trial biomarker study in ALS. A Phase 2 double-blind
proof-of-concept clinical study is now under preparation, with regulatory submissions and site readiness set for the end of Q2 2023.
The first patient is expected to be enrolled in Q3 2023. NeuroSense is collaborating with QuantalX, using direct electrophysiology imaging
technology (Delphi-MD) to provide multiple clinically objective and accurate measurements in the Phase 2 AD study.
NeuroSense reported results from a biomarker study conducted to evaluate the potential of its combination platform therapy for the treatment
of PD. NeuroSense observed a statistically significant (p= 0.002) decrease in levels of AGO2, a novel PD biomarker, in newly diagnosed
PD patients (n=15) when compared to the healthy control group. There were no significant changes observed in AGO2 levels of more
advanced stage PD patients, indicating that this trend could be related to disease onset. NeuroSense's platform combination therapy technology
has already shown a statistically significant increase of AGO2 in a Phase 2a clinical trial biomarker study in ALS. These results strengthen
the scientific rationale to develop NeuroSense's platform technology for PD. NeuroSense is now exploring potential co-development
for this asset with collaborators that have a core focus in PD.
collaboration with Dr. Ghazaleh Sadri-Vakili, MS, PhD and Massachusetts General Hospital's NeuroEpigenetics Lab explores the neurotherapeutic
effects of PrimeC by utilizing a novel in vitro model generated from post-mortem ALS brain tissue (synaptoneurosomes (SNs) system). The
objective of the collaborative studies is to expand the understanding of PrimeC's mechanism of action in attenuating ALS-related pathology,
specifically TDP-43 accumulation, autophagy defects, mitochondrial dysfunction, and oxidative stress.
to QuantalX's Delphi-MD providing multiple clinically objective measurements in NeuroSense's upcoming Phase 2 AD trial, the companies
agreed that Delphi-MD will be used for early diagnosis and ongoing monitoring of trial participants in NeuroSense's planned future pivotal
Phase 3 ALS trial, pending the successful conclusion of PARADIGM.
31, 2023, NeuroSense had cash and short-term deposits of $4.41 million.
A summary of NeuroSense's unaudited consolidated financial results
is included in the tables below.
NeuroSense Therapeutics
| Condensed Interim Unaudited Consolidated Statements of Financial Position As Of: |
| U.S. dollars in thousands |
| March 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash | 1,359 | 3,543 | ||||||
| Short term deposits | 3,053 | 3,547 | ||||||
| Other receivables | 567 | 255 | ||||||
| Restricted deposits | 39 | 36 | ||||||
| Total current assets | 5,018 | 7,381 | ||||||
| Non-current assets: | ||||||||
| Property, plant and equipment, net | 84 | 77 | ||||||
| Right of use assets | 210 | 229 | ||||||
| Non-current restricted deposit | 23 | 23 | ||||||
| Total non-current assets | 317 | 329 | ||||||
| Total assets | 5,335 | 7,710 | ||||||
| Liabilities and Equity | ||||||||
| Current liabilities: | ||||||||
| Trade payables | 419 | 498 | ||||||
| Other payables | 1,374 | 1,228 | ||||||
| Total current liabilities | 1,793 | 1,726 | ||||||
| Non Current liabilities: | ||||||||
| Long term lease liability | 126 | 147 | ||||||
| Liability in respect of warrants | 527 | 218 | ||||||
| 653 | 365 | |||||||
| Total liabilities | 2,446 | 2,091 | ||||||
| Shareholders' equity: | ||||||||
| Share premium and capital reserve | 27,564 | 26,405 | ||||||
| Accumulated deficit | (24,675 | ) | (20,786 | ) | ||||
| Total Shareholders' equity | 2,889 | 5,619 | ||||||
| Total liabilities and shareholders' equity | 5,335 | 7,710 |
NeuroSense Therapeutics Ltd.
| Condensed Interim Unaudited Consolidated Statements of Income and Comprehensive Loss |
| U.S. dollars in thousands except share and per share data |
| Three months | Three months | For the year | ||||||||||
| ended | ended | ended | ||||||||||
| March 31, | March 31, | December 31, | ||||||||||
| 2023 | 2022 | 2022 | ||||||||||
| Research and development expenses | (2,098 | ) | (1,296 | ) | (6,416 | ) | ||||||
| General and administrative expenses | (1,543 | ) | (1,968 | ) | (7,136 | ) | ||||||
| Operating loss | (3,641 | ) | (3,264 | ) | (13,552 | ) | ||||||
| Financing expenses | (310 | ) | (23 | ) | (45 | ) | ||||||
| Financing income | 62 | 572 | 1,257 | |||||||||
| Financing income (expenses), net | (248 | ) | 549 | 1,212 | ||||||||
| Net loss and comprehensive loss | (3,889 | ) | (2,715 | ) | (12,340 | ) | ||||||
| Basic and diluted net loss per share | (0.33 | ) | (0.24 | ) | (1.07 | ) |
NeuroSense Therapeutics
| Condensed Interim Unaudited Consolidated Statements of Changes in Equity |
| U.S. dollars in thousands |
| Ordinary | Share Premium And Capital | Accumulated | Total | |||||||||||||
| Shares | Reserve | Deficit | Equity | |||||||||||||
| Three months ended March 31, 2023: | ||||||||||||||||
| Balance as at January 1, 2023 | - | 26,405 | (20,786 | ) | 5,619 | |||||||||||
| Share-based compensation | - | 1,159 | - | 1,159 | ||||||||||||
| Net loss and comprehensive loss | - | - | (3,889 | ) | (3,889 | ) | ||||||||||
| Balance as at March 31, 2023 | - | 27,564 | (24,675 | ) | 2,889 | |||||||||||
| Three months ended March 31, 2022: | ||||||||||||||||
| Balance as at January 1, 2022 | - | 17,452 | (8,446 | ) | 9,006 | |||||||||||
| Share-based compensation | - | 1,597 | - | 1,597 | ||||||||||||
| Net loss and comprehensive loss | - | - | (2,715 | ) | (2,715 | ) | ||||||||||
| Cancelation of options | - | (96 | ) | - | (96 | ) | ||||||||||
| Exercise of warrants | - | 4,314 | - | 4,314 | ||||||||||||
| Balance as at March 31, 2022 | - | 23,267 | (11,161 | ) | 12,106 | |||||||||||
| For the year ended December 31, 2022: | ||||||||||||||||
| Balance as at January 1, 2022 | - | 17,452 | (8,446 | ) | 9,006 | |||||||||||
| Share-based compensation | - | 4,735 | - | 4,735 | ||||||||||||
| Net loss and comprehensive loss | - | - | (12,340 | ) | (12,340 | |||||||||||
| Cancelation of options | - | (96 | ) | - | (96 | ) | ||||||||||
| Exercise of warrants | - | 4,314 | - | 4,314 | ||||||||||||
| Balance as at December 31, 2022 | - | 26,405 | (20,786 | ) | 5,619 |
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company
focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes
that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent
one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date.
Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's
strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
For additional information, we invite you to visit our website and
Forward-Looking Statements
This press release contains "forward-looking statements"
that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words
such as "anticipate," "believe," "contemplate," "could," "estimate," "expect,"
"intend," "seek," "may," "might," "plan," "potential," "predict,"
"project," "target," "aim," "should," "will" "would," or the negative of these
words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based
on NeuroSense's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and
include statements regarding the timing of top-line results of, and the results of, the PARADIGM clinical trial and statements regarding
the co-development of our PD assets with collaborators with a core focus on PD. Further, forward-looking statements are subject to a number
of risks and uncertainties as a result of which actual results could differ materially and adversely from those anticipated or implied
in the forward looking statements. These risks include a delay in the reporting of top-line results from PARADIGM clinical trial; the
risk that the results of the trial will not be as anticipated; a delay in commencement of our Phase 2 study in AD; the risk that the final
results of PD Biomarker Study will not be consistent with the preliminary results; the risk that we will not be successful in signing
co-development agreement or other agreements with collaborators with a core focus on PD risks relating to NeuroSense's PrimeC development
programs; the potential for PrimeC to safely and effectively target ALS; the potential for PrimeC to safely and effectively target ALS;
preclinical and clinical data for PrimeC; the timing of current and future clinical trials, timing for reporting data; cash runway estimates;
the nature, strategy and focus of NeuroSense and further updates with respect thereto; the development and commercial potential of any
product candidates of NeuroSense; and that expenses for the remainder of 2023 will be higher than expected and other risks and uncertainties
set forth in NeuroSense's filings with the Securities and Exchange Commission (SEC), including NeuroSense's Annual Report on Form 20-F
filed with the SEC on March 22, 2023. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense
undertakes no duty to update such information except as required under applicable law.
For further information: Email: info@neurosense-tx.com, Tel: +972 (0)9